avipas2

3. September 2021

https://xl-protein.com/wordpress/wp-content/uploads/2021/02/XLplogo3.png 0 0 web28627236 https://xl-protein.com/wordpress/wp-content/uploads/2021/02/XLplogo3.png web286272362021-09-03 13:51:382021-09-03 13:51:57avipas2

Latest News:

XL-protein grants worldwide license to Grifols to develop a biopharmaceutical using PASylation® technology 10. June 2025
Akari Therapeutics Announces Pre-Clinical Development Progress Toward Potential IND on Long-Acting PAS-Nomacopan for Geographic Atrophy (GA) 15. February 2023
Bavarian Research Foundation supports the development of an immunosuppressive PASylated antibody fragment to support cardiac xenotransplantation 28. September 2022

Partnering contact:

XL-protein GmbH
Uli Binder
Lise-Meitner-Str. 30
85354 Freising
Germany

Phone: +49 (0) 8161 53730-90
Fax: +49 (0) 8161 53730-99
E-mail: bd@xl-protein.com

Web: www.xl-protein.com

Link to Mail

Scroll to top